Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
10X Genomics Inc (TXG) Insider Trading Activity
Healthcare • Health Information Services • 1,259 employees
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Total Value
-$487,887.61
Total Shares
57,377
Average Trade Value
-$40,657.30
Most Active Insider
Saxonov Serge
Total Activity: $243,665
Largest Single Transaction
$152,053
by Saxonov Serge on Aug 22, 2024
30-Day Activity
2 Transactions
Volume: 12,500 shares
Value: $171,098
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
---|---|---|---|---|---|---|
Chief Executive Officer
|
Nov 22, 2024 | 6,693 | $91,612 | 872,574 (-0.8%) | Sale | |
See Remarks
|
Nov 22, 2024 | 5,807 | $79,485 | 339,897 (-1.7%) | Sale | |
Aug 30, 2024 | 19,002 | $0 | 19,002 (+100.0%) | Grant | ||
Aug 22, 2024 | 2,961 | $66,710 | 143,242 (-2.1%) | Sale | ||
See Remarks
|
Aug 22, 2024 | 4,351 | $98,027 | 345,704 (-1.3%) | Sale | |
Chief Executive Officer
|
Aug 22, 2024 | 6,749 | $152,053 | 882,467 (-0.8%) | Sale | |
Jul 31, 2024 | 21,691 | $0 | 21,691 (+100.0%) | Grant | ||
Jun 11, 2024 | 8,649 | $0 | 13,259 (+65.2%) | Grant | ||
Jun 11, 2024 | 8,649 | $0 | 344,250 (+2.5%) | Grant | ||
Jun 11, 2024 | 8,649 | $0 | 180,259 (+4.8%) | Grant | ||
Jun 11, 2024 | 8,649 | $0 | 13,259 (+65.2%) | Grant | ||
Jun 11, 2024 | 8,649 | $0 | 41,092 (+21.0%) | Grant |